Kapiva, a direct-to-consumer (D2C) Ayurveda brand, has raised $60 million in Series D funding. The round was co-led by 360 ONE Asset and Vertex Growth, with support from existing investors Vertex Ventures and 3one4 Capital.
Out of the total, $28 million came in as fresh capital (primary infusion) for the company, while $32 million was a secondary deal, giving early investors a successful exit.
The funds will be used to expand research and development (R&D), increase manufacturing capacity, strengthen brand growth, and build a health-tech platform to offer more personalized healthcare.
Kapiva was founded in 2016 by Ameve Sharma and Shrey Badhani.
The company offers 100+ ayurvedic nutrition products like supplements, gummies, capsules, and skincare items, along with doctor consultations.
“The top 5 categories contribute to 96-97% of revenue, which comprises diabetes, then the gym supplement category, followed by energy supplements, heart and liver, ” Ameve Sharma, cofounder of Kapiva.
The startup says its diabetes supplement is the best-selling product in India in its category.
The company has grown over 80% every year for the last three years, with a revenue of ₹5.5 billion ($66 million).
Its products cover diabetes care, sports nutrition, liver health, and general wellness. They are sold online, through its own website, in 40,000 retail stores across India, and also in the U.S., Middle East, and Europe.
Read more- Kela Buys AI Startup Pelanor in Deal Worth Tens of Millions
